AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05008991 — intervention group
Intervention type: DEVICE
Intervention: Spirometry
Description: Spirometry assesses the integrated mechanical function of the lung, chest wall, respiratory muscles, and airways by measuring the total volume of air exhaled from a full lung (total lung capacity \[TLC\]) to maximal expiration (residual volume \[RV\]). This volume, the forced vital capacity (FVC) and the forced expiratory volume in the first second of the forceful exhalation (FEV1), should be repeatable to within 0.15 L upon repeat efforts in the same measurement unless the largest value for either parameter is less than 1 L. In this case, the expected repeatability is to within 0.1 L of the largest value.
Study NCT05210790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT05210790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rusfertide
Description: Experimental drug
Study NCT06022016 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: For each person (index case or related) included in this study:
Description: * an health questionnaire will be completed in order to gather information on the participant's medical history and lifestyle.~* a saliva sample will be taken (if applicable) so that a genetic analysis can be performed.
Study NCT04796246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leap Motion Controller
Description: Training with the Leap Motion Controller instrument will be carried out first for 5 minutes, for a presentation and interaction of the virtual immersion with it, in the initial meeting. After the second meeting, the attendance protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games it was adopted about 2 minutes of rest.
Study NCT04796246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leap Motion Controller
Description: Training with the Leap Motion Controller instrument will be carried out first for 5 minutes, for a presentation and interaction of the virtual immersion with it, in the initial meeting. After the second meeting, the attendance protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games it was adopted about 2 minutes of rest.
Study NCT04796246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: The conventional physiotherapy intervention will be based on the same activities developed (MMSS movements) of the IG: - First, attach pins with magnets with moving disc and after 1 minute and 25 seconds remove flower petals from inside a tube. The movements performed will be fine motricity, related to the tweezers handling (thumb and forefinger), alternating hands after 2 minutes and 30 minutes of play; - Hitting your hands on suddenly raised rulers, performing bilateral flexion / extension movements of the wrist simultaneously and alternating hands after 2 minutes and 30 minutes of play.
Study NCT04796246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: The conventional physiotherapy intervention will be based on the same activities developed (MMSS movements) of the IG: - First, attach pins with magnets with moving disc and after 1 minute and 25 seconds remove flower petals from inside a tube. The movements performed will be fine motricity, related to the tweezers handling (thumb and forefinger), alternating hands after 2 minutes and 30 minutes of play; - Hitting your hands on suddenly raised rulers, performing bilateral flexion / extension movements of the wrist simultaneously and alternating hands after 2 minutes and 30 minutes of play.
Study NCT05984355 — intervention group
Intervention type: OTHER
Intervention: Individual interviews
Description: Discussion between the searcher and the participant about representations and acceptability about a potential application and captors which suggest a Walking itinerary
Study NCT05874180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW6013
Description: Drug: DW6013 Single oral administration of DW6013 in fed condition~Drug: Linagliptin and Metformin Single oral administration of Linagliptin and Metformin in fed condition
Study NCT06466174 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 1 to Probiotic A
Description: 42 day Crossover study design between Placebo 1 and Probiotic A (n = 25)
Study NCT06466174 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic A to Placebo 1
Description: 42 day Crossover study design between Probiotic A and Placebo 1 (n = 25)
Study NCT06466174 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 2 to Probiotic B
Description: 42 day Crossover study design between Placebo 2 and Probiotic B (n = 25)
Study NCT06466174 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic B to Placebo 2
Description: 42 day Crossover study design between Probiotic B and Placebo 2 (n = 25)
Study NCT06148298 — intervention group
Intervention type: OTHER
Intervention: Non-Human Subject Research study.
Description: This is a Non-Human Subject Research study. There is no intervention. All participants are de-identified.
Study NCT06240949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positional Release Technique
Description: Positional Release Technique will be applied on iliopsoas muscle. Treatment time will be 30 minutes per session, 4 times/week for 4 weeks in the hospital setting.
Study NCT06240949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Pressure Technique
Description: Manual Pressure Technique will be applied on iliopsoas muscle. Treatment time will be 30 minutes per session, 4 times/week for 4 weeks in the hospital setting.
Study NCT05933460 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary supplement with probiotics, prebiotics, magnesium and saffron extract
Description: A sachet of a combination of 4 strains of probiotics (1billion CFU) (Lactobacillus rhamnosus, Bifidobacterium animalis subscp. lactis, Bifidobacterium breve, Bifidobacterium longum), Fructooligosaccharides 100mg, Magnesium 75mg and Saffron extract 28mg was administered 3 times per day
Study NCT05933460 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: dietary supplement with probiotics, prebiotics, magnesium
Description: A sachet of a combination of 4 strains of probiotics (1billion CFU) (Lactobacillus rhamnosus, Bifidobacterium animalis subscp. lactis, Bifidobacterium breve, Bifidobacterium longum), Fructooligosaccharides 100mg, Magnesium 75mg was administered 3 times per day
Study NCT06236386 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: VR Experience
Description: VR headset and video experience.
Study NCT05447208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: Growth hormone is supplemented before and during the ovarian stimulation till the day of oocyte retrieval
Study NCT05447208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
Study NCT05447208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
Study NCT06056583 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cimetidine 200 MG
Description: Cimetidine will serve as the probe drug
Study NCT06159972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoFLIP
Description: EndoFLIP is a small balloon catheter that is inserted through the endoscope at the time of endoscopy.
Study NCT04845607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone Injection
Description: Amiodarone continuous infusion during 24 hours from return of spontaneous circulation.
Study NCT04929327 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self etch Pit and fissure sealant application (prevent seal)
Description: Sealing deep pits and fissures
Study NCT04929327 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self etch Pit and fissure sealant application (prevent seal) with prior sandblasting
Description: Sandblasting before Sealing deep pits and fissures
Study NCT04929327 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total etch resin based sealant ultraseal xt
Description: Sealing deep pits and fissures
Study NCT04795037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU06-1004, Single dose
Description: Single dose of CU06-1004, 7 dose levels, oral capsule : 6 Cohorts (100mg, 300mg, 600mg, 900mg, 1200mg, 300mg bid) + 1 Cohort (Food effect)＊~＊Cohort S7(TBD mg) will receive a single oral dose of CU06-1004 or placebo under fed conditions. When administered under fed conditions, CU06-1004 or placebo will be administered following a high-fat/high-calorie breakfast. Cohort S7 will be conducted following completion of Cohort S5
Study NCT04795037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU06-1004, Multiple doses
Description: Multiple doses of CU06-1004, 7 days, 3 dose levels＊, oral capsule~＊The dose levels, regimen (i.e., schedule), and conditions (i.e., fasted versus fed conditions) will be determined based on the safety, tolerability, and plasma PK data from SAD
Study NCT04795037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to CU06-1004, oral capsule
Study NCT06254040 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will consume 1 dissolving powder pack per day diluted in water, with breakfast, without any restriction in the diet or in their life habits.
Study NCT06254040 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mixture of extracts and DHA
Description: Each participant will consume 1 dissolving powder pack per day diluted in water, with breakfast, without any restriction in the diet or in their life habits.
Study NCT05759858 — intervention group
Intervention type: OTHER
Intervention: None of intervention
Description: None of the interventions was applied.
Study NCT06453759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional electrodes into bilateral anterior, centromedian and pulvinar thalamic nuclei
Description: The centromedian, anterior and pulvinar nuclei on each side will be chosen as target for new electrodes; up to 6 additional electrodes may be added but, where possible, existing electrode trajectories will be extended to facilitate recording.~At the beginning of the recording process, usually within the first 24-48 hours of implantation, we will conduct 2 study-specific stimulation experiments:~1. Single pulse electrical stimulation (SPES):~2. N-of-1 trials of simulated DBS: We will simulate high (130Hz) and low (6Hz) frequency DBS currents from each pair of thalamic nuclei (always bilateral) and record spontaneous interictal neuronal activity in all other cortical contacts for 15 minutes. We will also record SPES from each of the cortical contacts.
Study NCT04926948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Immunotherapy
Study NCT04926948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04926948 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT06027008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Insufflation-Exsufflation
Description: MI-E will be applied twice a day in invasively ventilated patients. Since the severity of illness can change in the ICU, each day the attending nurse will check for clinical reasons to not apply MI-E with regard to safety. The following clinical criteria are predefined as a reason to refrain from MI-E at that day:~* severe ventilator instability (requiring > 12 cm H2O PEEP and dependency of > 60% FiO2);~* severe hemodynamic instability (a need for large and sustained increase in continuous administration of intravenous vasopressive medication that are adjusted on a frequent basis in each nursing shift);~* extra corporal membrane oxygenation (ECMO); and~* deeply sedated patient (RASS score ≤ -4).
Study NCT05846815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARVO 2.0 WEB
Description: Medical device software where the subject navigates in a virtual apartment, with the goal of performing the tasks given by a cartoon dragon character. The child is asked to perform the subtasks in the given order, except for the subtasks to be completed at a certain time or after a certain sound cue, but the completion order does not influence the scoring. One task scenario lasts until all subtasks are correctly performed or until the time limit of 60 s is reached.~The classification whether the subject belong to typically developed population is based on quantitative neurological performance indicators produced during the game. However, even if the activity performed is differential diagnostics, ARVO does not create any medical diagnosis. It shall be also noted that in the present clinical investigation, the interpretation of the results regarding child's ADHD susceptibility is not performed.
Study NCT05846815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conners Continuous Performance Test 3rd Edition™ (CPT 3)
Description: Subjects are required to respond by pressing the spacebar or the appropriate key on the mouse when any letter other than the letter X appears on the monitor. The Conners CPT 3 presents 14-minute, 360 scored stimuli trials (i.e., individual letters) on the screen, with 1, 2, or 4 sec. between the presentation of letters (i.e., the interstimulus interval; ISI). The 360 trials are divided into 6 blocks, with 3 sub-blocks each consisting of 20 trials. Each block lasts approximately 2 min and 20 sec. Scores and Score Dimensions of Attention Measured: Inattentiveness, Impulsivity, Sustained Attention and Vigilance. The Conners CPT 3 produces computer-generated reports that describe the respondent's performance.~It shall be also noted that in the present clinical investigation, the interpretation of the results regarding child's ADHD susceptibility is not performed
Study NCT03826758 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: E-DYNAMIC Clinical Decision Support
Description: Clinical decision support system
Study NCT05746468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological assessment and intervention
Description: The MBI-EMI app will include five main parts, including virtual counselor, intervention library, weekly mindfulness practice, assessment bank and daily emotion log. In the eight weeks, the virtual counselor will initiate the conversation every day for three times (morning, afternoon and evening) to check the status of the participants. If the participants responded, the virtual counselor would invite the participants to rate their level of depression, stress and anxiety and then recommend appropriate mindfulness practice in the intervention library, such as 3-minute breathing space or mindful eating. The conversation between the virtual counselor and participants will be in the format of menu list and participants can easily choose from different options.
Study NCT05746468 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audio-based Mindfulness intervention
Description: The control group will receive audio recordings of how to practice mindfulness at home.
Study NCT05612009 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Toothpastes
Description: Signal Expert Protection: Conventional toothpaste including Sodium Lauryl Sulphate and fluoride.~Colgate Hemp Seed Oil: Herbal toothpaste including hemp seed oil and also fluoride.~Gumgumix: Herbal toothpaste including ginger extract (no fluoride).
Study NCT06334640 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Three questionaires
Description: Berlin, Pittsburgh and Epworth tests administered during study visit
Study NCT04430439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial stress
Description: The TSST is a 15 minute standardized lab-based challenge task that involves speech preparation, speech delivery while being evaluated by strangers and video taped, and complex mental arithmetic with critiques if errors are made.
Study NCT04430439 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control non-stress
Description: Participants will have a relaxed 15 minute conversation with a familiar research team member.
Study NCT05160766 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty(BTN162b2)
Description: Single booster shot (4th dose) of already approved BioNTech/ Pfizer vaccine that protect against COVID-19 infection
Study NCT05160766 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Spikevax (mRNA-1273)
Description: Single booster shot (4th dose) of already approved Moderna vaccine that protect against COVID-19 infection
Study NCT06006026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Hydrochloride 10 MG/ML [Naropin]
Description: According to the specified dosage, dilute 1% ropivacaine to 0.2% and inject 1/2 of the total amount on each side.
Study NCT05476783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB006
Description: Clear to slightly opalescent, sterile solution for injection
Study NCT06654752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate Oral Antibiotics
Description: Increase airway clearance and start 14 days of preselected oral antibiotics right away
Study NCT06654752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Treatment: Oral Antibiotics only if Additional Treatment needed
Description: Increase airway clearance and start preselected oral antibiotics later if symptoms get worse or do not get better according to prespecified criteria
Study NCT06284772 — intervention group
Intervention type: OTHER
Intervention: Questionnaire and fecal sampling
Description: The participants will be mailed a fecal collection kit and a 20-page health questionnaire. This questionnaire will include the similar questions concerning health, lifestyles, and diet as in 2002.
Study NCT06284772 — intervention group
Intervention type: OTHER
Intervention: Health examination
Description: This examination will include measurements for anthropometrics, cognition (MoCA, Stroop, DSST), and blood pressure. The participants will undergo blood draw for laboratory analyses of CMD risk factors, such as blood lipids, glucose metabolism (fasting glucose, HbA1c, and fasting insulin), liver enzymes (GGT, ALT, and AST), inflammation (hs-CRP), and cardiac markers (proBNP and hs-TnI). We will perform ultrasound imaging for hepatic fibrosis.
Study NCT06128369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Ophthalmic Suspension
Description: Ophthalmic Suspension,1.5% \[15 mg/mL\] Subjects will dose 1 drop of OCS-01 in the study eye once daily for 14 days, beginning 1-day post-surgery in the operated eye (administration of first dose will be performed in the clinic on Day 1).
Study NCT06128369 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of OCS-01
Description: inert vehicle of OCS-01 ophthalmic suspension Subjects will dose 1 drop of OCS-01 in the study eye once daily for 14 days, beginning 1-day post-surgery in the operated eye (administration of first dose will be performed in the clinic on Day 1).
Study NCT06706219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan plus pembrolizumab
Description: Participants meeting the inclusion criteria will receive pembrolizumab 200 mg IV on D1, Q3W + SKB264 4mg/kg IV on D1, D15 and D29，Q2W for 12 weeks as induction therapy.~Subjects who receive radical radiotherapy will undergo 8 cycles of pembrolizumab 200 mg IV on D1, Q3W; For those receiving surgical treatment, pembrolizumab is selected for adjuvant therapy for pCR patients, and SKB264 combination with pembrolizumab is selected non-PCR patients.
Study NCT06727383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood collection
Description: standard blood test procedures
Study NCT06727383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukapheresis
Description: Leukapheresis is the procedure that allows the separation and collection of hematopoietic stem cells (HSCs) from peripheral blood. The collection takes place through a machine called a cell separator: it uses centrifugal force to separate the mononuclear cells from all the other cells in the blood and plasma.
Study NCT06727292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplement
Description: Instant drink in a powder form presented in a sachet to be disolved in a glass of water (200 ml).
Study NCT06727292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Instant drink in powder form in a sachet to be disolved in a glass of water (200ml)
Study NCT06726213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walk and talk
Description: An hour long walk at a slow pace lead by a trained walking leader.
Study NCT06725940 — intervention group
Intervention type: DEVICE
Intervention: 68Ga-GZMB PET/CT
Description: 68Ga-GZMB PET/CT